Minnesota Medical Technologies Corporation Announces European Distribution Agreement

Minnesota Medical Technologies Corporation (Minnesota Medical), a medical device manufacturing company based in Stewartville, MN, U.S, and Wellspect Healthcare (Wellspect), headquartered in Mölndal, Sweden and a part of U.S. based Dentsply Sirona, have entered into an agreement for the distribution of Minnesota Medical’s fecal incontinence insert throughout Europe.

David A. Jonas, Minnesota Medical’s CEO commented: “We are pleased to announce this exciting, strategic partnership with Wellspect.

This collaboration puts our innovative technology in the hands of one of the world’s leading providers of continence care solutions.  Wellspect has the infrastructure and relationships to immediately begin marketing and distributing this life-changing product throughout Europe. Without question, this will accelerate our growth curve.”

The completion of this strategic distribution agreement provides Wellspect the exclusive rights to distribute Minnesota Medical’s innovative fecal incontinence insert device in markets across Europe. The product, which has been approved for sale in Europe, will be marketed under Wellspect’s Navina™ brand.

“Supporting our customers and users is at the heart of everything we do, we are constantly searching for collaborations with companies that have unique and innovative products in our core areas. It is therefore with pleasure that we can now launch the Navina Incontinence Insert, which is the result of our strategic collaboration with Minnesota Medical Technologies,” says Svenn Poulsen, Group Vice President, Wellspect Healthcare.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version